1-[3-[6-(1-methylpyrazol-4-yl)-7-(trifluoromethyl)-3,4-dihydro-2H-quinolin-1-yl]-1-[(3S)-tetrahydrofuran-3-yl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl]ethanone

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-[3-[6-(1-methylpyrazol-4-yl)-7-(trifluoromethyl)-3,4-dihydro-2H-quinolin-1-yl]-1-[(3S)-tetrahydrofuran-3-yl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl]ethanone
• 英文别名: 1-[3-[6-(1-methylpyrazol-4-yl)-7-(trifluoromethyl)-3,4-dihydro-2H-quinolin-1-yl]-1-[(3S)-oxolan-3-yl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl]ethanone
• 化学式: C₂₆H₂₉F₃N₆O₂
• 分子量: 514.55
• InChiKey: BPGFXHXXEIUDSE-IBGZPJMESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  37
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  68.4
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  ethyl 3-((tert-butoxycarbonyl)(2-cyanoethyl)amino)propanoate 在 dichloro(1,3-bis(2,6-bis(3-pentyl)phenyl)imidazolin-2-ylidene)(3-chloropyridyl)palladium(II) 、 sodium hydride 、 caesium carbonate 、 一水合肼 、 三氟乙酸 、 copper(ll) bromide 、 sodium t-butanolate 、 亚硝酸异戊酯 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 、 乙腈 为溶剂， 反应 29.33h， 生成 1-[3-[6-(1-methylpyrazol-4-yl)-7-(trifluoromethyl)-3,4-dihydro-2H-quinolin-1-yl]-1-[(3S)-tetrahydrofuran-3-yl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl]ethanone
  参考文献：
  名称：

  GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP)

  摘要：

  Inhibition of the bromodomain of the transcriptional regulator CBP/P300 is an especially interesting new therapeutic approach in oncology. We recently disclosed in vivo chemical tool 1 (GNE-272) for the bromodomain of CBP that was moderately potent and selective over BRD4(1). In pursuit of a more potent and selective CBP inhibitor, we used structure based design. Constraining the aniline of 1 into a tetrahydroquinoline motif maintained potency and increased selectivity 2-fold. Structure-activity relationship studies coupled with further structure-based design targeting the LPF shelf, BC loop, and KAc regions allowed us to significantly increase potency and selectivity, resulting in the identification of non-CNS penetrant 19 (GNE-781, TR-FRET IC50 = 0.94 nM, BRET IC50 = 6.2 nM; BRD4(1) IC50 = 5100 nM) that maintained good in vivo PK properties in multiple species. Compound 19 displays antitumor activity in an AML tumor model and was also shown to decrease Foxp3 transcript levels in a dose dependent manner.

  DOI：

  10.1021/acs.jmedchem.7b00796

文献信息

• GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP)
  作者：F. Anthony Romero、Jeremy Murray、Kwong Wah Lai、Vickie Tsui、Brian K. Albrecht、Le An、Maureen H. Beresini、Gladys de Leon Boenig、Sarah M. Bronner、Emily W. Chan、Kevin X. Chen、Zhongguo Chen、Edna F. Choo、Kyle Clagg、Kevin Clark、Terry D. Crawford、Patrick Cyr、Denise de Almeida Nagata、Karen E. Gascoigne、Jane L. Grogan、Georgia Hatzivassiliou、Wei Huang、Thomas L. Hunsaker、Susan Kaufman、Stefan G. Koenig、Ruina Li、Yingjie Li、Xiaorong Liang、Jiangpeng Liao、Wenfeng Liu、Justin Ly、Jonathan Maher、Colin Masui、Mark Merchant、Yingqing Ran、Alexander M. Taylor、John Wai、Fei Wang、Xiaocang Wei、Dong Yu、Bing-Yan Zhu、Xiaoyu Zhu、Steven Magnuson

  DOI：10.1021/acs.jmedchem.7b00796

  日期：2017.11.22

  Inhibition of the bromodomain of the transcriptional regulator CBP/P300 is an especially interesting new therapeutic approach in oncology. We recently disclosed in vivo chemical tool 1 (GNE-272) for the bromodomain of CBP that was moderately potent and selective over BRD4(1). In pursuit of a more potent and selective CBP inhibitor, we used structure based design. Constraining the aniline of 1 into a tetrahydroquinoline motif maintained potency and increased selectivity 2-fold. Structure-activity relationship studies coupled with further structure-based design targeting the LPF shelf, BC loop, and KAc regions allowed us to significantly increase potency and selectivity, resulting in the identification of non-CNS penetrant 19 (GNE-781, TR-FRET IC50 = 0.94 nM, BRET IC50 = 6.2 nM; BRD4(1) IC50 = 5100 nM) that maintained good in vivo PK properties in multiple species. Compound 19 displays antitumor activity in an AML tumor model and was also shown to decrease Foxp3 transcript levels in a dose dependent manner.